CoChat
Sign Up
Cited by 112

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice

Regina, Anthony, Demeule, Michel, Tripathy, Sasmita, Lord-Dufour, Simon, Currie, Jean-Christophe, Iddir, Mustapha, Annabi, Borhane, Castaigne, Jean-Paul, Lachowicz, Jean E.·2015·Molecular Cancer Therapeutics
DOI 10.1158/1535-7163.mct-14-0399

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Anti-HER2 monoclonal antibodies (mAb) have been shown to reduce tumor size and increase survival in patients with breast cancer, but they are ineffective against brain metastases due to poor brain penetration. In previous studies, we identified a peptide, known as Angiopep-2 (An2), which crosses the blood–brain barrier (BBB) efficiently via receptor-mediated transcytosis, and, when conjugated, endows small molecules and peptides with this property. Extending this strategy to higher molecular weight biologics, we now demonstrate that a conjugate between An2 and an anti-HER2 mAb results in a new chemical entity, ANG4043, which retains in vitro binding affinity for the HER2 receptor and antiproliferative potency against HER2-positive BT-474 breast ductal carcinoma cells. Unlike the native mAb, ANG4043 binds LRP1 clusters and is taken up by LRP1-expressing cells. Measuring brain exposure after intracarotid delivery, we demonstrate that the new An2–mAb conjugate penetrates the BBB with a rate of brain entry (Kin) of 1.6 × 10−3 mL/g/s. Finally, in mice with intracranially implanted BT-474 xenografts, systemically administered ANG4043 increases survival. Overall, this study demonstrates that the incorporation of An2 to the anti-HER2 mAb confers properties of increased uptake in brain endothelial cells as well as BBB permeability. These characteristics of ANG4043 result in higher exposure levels in BT-474 brain tumors and prolonged survival following systemic treatment. Moreover, the data further validate the An2–drug conjugation strategy as a way to create brain-penetrant biologics for neuro-oncology and other CNS indications. Mol Cancer Ther; 14(1); 129–40. ©2014 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-14-0399

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 48

  1. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 · DOI
  2. Gonzalez-Angulo, 2009, High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller, J Clin Oncol, 27, 5700, 10.1200/JCO.2009.23.2025 · DOI
  3. Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 · DOI · Paper page
  4. Pegram, 1998, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol, 16, 2659, 10.1200/JCO.1998.16.8.2659 · DOI
  5. Shepard, 2008, Herceptin, Handb Exp Pharmacol, 183, 10.1007/978-3-540-73259-4_9 · DOI
  6. Yin, 2011, Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials, PLoS ONE, 6, e21030, 10.1371/journal.pone.0021030 · DOI
  7. Duchnowska, 2005, Central nervous system metastases in breast cancer patients administered trastuzumab, Cancer Treat Rev, 31, 312, 10.1016/j.ctrv.2005.04.008 · DOI
  8. Fuchs, 2002, HER2 in brain metastases: issues of concordance, survival, and treatment, J Clin Oncol, 20, 4130, 10.1200/JCO.2002.04.016 · DOI
  9. Wang, 2008, Monoclonal antibody pharmacokinetics and pharmacodynamics, Clin Pharmacol Ther, 84, 548, 10.1038/clpt.2008.170 · DOI · Paper page
  10. Lin, 1999, Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor, J Pharmacol Exp Ther, 288, 371, 10.1016/S0022-3565(24)37962-5 · DOI
  11. Gatson, 2012, Anti-angiogenic gene therapy in the treatment of malignant gliomas, Neurosci Lett, 527, 62, 10.1016/j.neulet.2012.08.001 · DOI
  12. Kinoshita, 2006, Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption, Proc Natl Acad Sci U S A, 103, 11719, 10.1073/pnas.0604318103 · DOI
  13. Li, 2014, Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells, Pharm Res, 31, 86, 10.1007/s11095-013-1134-0 · DOI
  14. Shin, 2012, Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series, Neurosurg Clin N Am, 23, 323, 10.1016/j.nec.2012.01.008 · DOI
  15. Hu, 2010, Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models, PLoS ONE, 5, e10108, 10.1371/journal.pone.0010108 · DOI
  16. Ningaraj, 2009, Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model, Cancer Biol Ther, 8, 1924, 10.4161/cbt.8.20.9490 · DOI
  17. Boado, 2013, Blood–brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey, Bioconjug Chem, 24, 1741, 10.1021/bc400319d · DOI
  18. Niewoehner, 2014, Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle, Neuron, 81, 49, 10.1016/j.neuron.2013.10.061 · DOI · Paper page
  19. Pflanzner, 2011, LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier, Neurobiol Aging, 32, 2323 e1, 10.1016/j.neurobiolaging.2010.05.025 · DOI · Paper page
  20. Uchida, 2011, Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors, J Neurochem, 117, 333, 10.1111/j.1471-4159.2011.07208.x · DOI · Paper page
  21. Demeule, 2008, Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2, J Neurochem, 106, 1534, 10.1111/j.1471-4159.2008.05492.x · DOI · Paper page
  22. Demeule, 2008, Identification and design of peptides as a new drug delivery system for the brain, J Pharmacol Exp Ther, 324, 1064, 10.1124/jpet.107.131318 · DOI
  23. Che, 2010, New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration, J Med Chem, 53, 2814, 10.1021/jm9016637 · DOI · Paper page
  24. Regina, 2008, Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2, Br J Pharmacol, 155, 185, 10.1038/bjp.2008.260 · DOI
  25. Bertrand, 2011, Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1, Br J Cancer, 105, 1697, 10.1038/bjc.2011.427 · DOI · Paper page
  26. Kurzrock, 2012, Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors, Mol Cancer Ther, 11, 308, 10.1158/1535-7163.MCT-11-0566 · DOI · Paper page
  27. Dagenais, 2000, Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice, J Cereb Blood Flow Metab, 20, 381, 10.1097/00004647-200002000-00020 · DOI
  28. Triguero, 1990, Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins, J Neurochem, 54, 1882, 10.1111/j.1471-4159.1990.tb04886.x · DOI
  29. Neels, 1999, The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties, J Biol Chem, 274, 31305, 10.1074/jbc.274.44.31305 · DOI · Paper page
  30. Takasato, 1984, An in situ brain perfusion technique to study cerebrovascular transport in the rat, Am J Physiol, 247, H484
  31. Dagenais, 2009, P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model, Eur J Pharm Sci, 38, 121, 10.1016/j.ejps.2009.06.009 · DOI
  32. Varatharajan, 2009, The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research, Antiviral Res, 82, A99, 10.1016/j.antiviral.2008.12.013 · DOI
  33. Baselga, 1998, Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res, 58, 2825
  34. Moulder, 2001, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo, Cancer Res, 61, 8887
  35. Wang, 2005, In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer, Breast Cancer Res Treat, 92, 251, 10.1007/s10549-005-3375-z · DOI
  36. Yang, 2003, Crystalline monoclonal antibodies for subcutaneous delivery, Proc Natl Acad Sci U S A, 100, 6934, 10.1073/pnas.1131899100 · DOI
  37. Khalili, 2005, Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer, Oncogene, 24, 6657, 10.1038/sj.onc.1208790 · DOI
  38. Thomas, 2009, Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer, Pharm Res, 26, 2486, 10.1007/s11095-009-9964-5 · DOI
  39. Demeule, 2014, Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties, J Clin Invest, 124, 1199, 10.1172/JCI70647 · DOI
  40. Sun, 2012, Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome, Biomaterials, 33, 916
  41. Xin, 2012, Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles, Biomaterials, 33, 8167, 10.1016/j.biomaterials.2012.07.046 · DOI
  42. Shao, 2010, Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain, J Control Release, 147, 118, 10.1016/j.jconrel.2010.06.018 · DOI
  43. Couch, 2013, Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier, Sci Transl Med, 5, 183ra57, 10.1126/scitranslmed.3005338 · DOI
  44. Kodack, 2012, Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases, Proc Natl Acad Sci U S A, 109, E3119, 10.1073/pnas.1216078109 · DOI · Paper page
  45. Bartsch, 2007, Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer, J Neurooncol, 85, 311, 10.1007/s11060-007-9420-5 · DOI
  46. Stemmler, 2007, Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anti-Cancer Drugs, 18, 23, 10.1097/01.cad.0000236313.50833.ee · DOI
  47. Eiseman, 1994, Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice, Cancer Chemother Pharmacol, 34, 465, 10.1007/BF00685656 · DOI
  48. Lewis Phillips, 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate, Cancer Res, 68, 9280, 10.1158/0008-5472.CAN-08-1776 · DOI

Cited by

Sorted by citations

See all 112

Metadata

Authors
Regina, A., Demeule, M., Tripathy, S., Lord-Dufour, S., Currie, J.-C., Iddir, M., Annabi, B., Castaigne, J.-P., & Lachowicz, J. E.
Affiliations
  • 1Angiochem Inc., Montréal, Québec, Canada.
  • 2Département de Chimie, Université du Québec à Montréal, Montréal, Québec, Canada.
Venue
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research (AACR)
Published
2015-01-01
Volume
14
Issue
1
Pages
129-140
ISSN
  • 1535-7163
  • 1538-8514
DOI
10.1158/1535-7163.mct-14-0399
Cited by
112
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review